BioCryst (BCRX) Berotralstat Continues To Appear Approvable By YE And Has $500MM+ Potential - Piper Sandler
Tweet Send to a Friend
Piper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $10.00 price target on BioCryst Pharma (NASDAQ: BCRX), saying ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
